Key result
An integrative transomics approach identified multiple candidate genes for heart failure traits, with rs77059055 in TPM1 remaining statistically significant in the UK Biobank (OR 0.83; P=0.002).
Why the study?
Heart failure can arise from metabolic, structural, and signaling pathway alterations, but its genetic architecture remains incompletely understood.
Cohort (n=8,372)
Yes
Effect estimate: OR 0.83
p-value: p=0.002
An integrated transomics approach identified novel genetic and molecular contributors to heart failure and its echocardiographic precursors, highlighting potential new pathways for HF pathogenesis.
Supports novel HF pathways via transomics; hypothesis-generating and requires prospective validation before clinical use.
Background: Heart failure (HF) may arise from alterations in metabolic, structural, and signaling pathways, but its genetic architecture is incompletely understood. To elucidate potential genetic contributors to cardiac remodeling and HF, we integrated genome-wide single-nucleotide polymorphisms, gene expression, and DNA methylation using a transomics analytical approach. Methods: We used robust rank aggregation (where the position of a certain gene in a rank order list [based on statistical significance level] is tested against a randomly shuffled rank order list) to derive an integrative transomic score for each annotated gene associated with a HF trait. Results: We evaluated ≤8372 FHS (Framingham Heart Study) participants (54% women; mean age, 55±17 years). Of these, 62 (0.7%) and 35 (0.4%) had prevalent HF with reduced ejection fraction and HF with preserved left ventricular ejection fraction, respectively. During a mean follow-up of 8.5 years (minimum–maximum, 0.005–18.6 years), 223 (2.7%) and 234 (2.8%) individuals developed incident HF with reduced ejection fraction and HF with reduced ejection fraction, respectively. Top genes included MMP20 and MTSS1 (promotes actin assembly at intercellular junctions) for left ventricular systolic function; ITGA9 (receptor for VCAM1 [vascular cell protein 1]) and C5 for left ventricular remodeling; NUP210 (expressed during myogenic differentiation) and ANK1 (cytoskeletal protein) for diastolic function; TSPAN16 and RAB11FIP3 (involved in regulation of actin cytoskeleton) for prevalent HF with reduced ejection fraction; ANKRD13D and TRIM69 for incident HF with reduced ejection fraction; HPCAL1 and PTTG1IP for prevalent HF with reduced ejection fraction; and ZNF146 (close to the COX7A1 enzyme) and ZFP3 (close to SLC52A1 —the riboflavin transporter) for incident HF with reduced ejection fraction. We tested the HF-related top single-nucleotide polymorphisms in the UK biobank, where rs77059055 in TPM1 (minor allele frequency, 0.023; odds ratio, 0.83; P =0.002) remained statistically significant upon Bonferroni correction. Conclusions: Our integrative transomics approach offers insights into potential molecular and genetic contributors to HF and its precursors. Although several of our candidate genes have been implicated in HF in animal models, independent replication is warranted.
No takes yet. Share an insight, caveat, or question.
Andersson et al. (2019) conducted a cohort in Heart failure and its echocardiographic precursors (n=8,372). Integrative transomics approach (genome-wide SNPs, gene expression, DNA methylation) was evaluated on Identification of genetic contributors to cardiac remodeling and heart failure traits (OR 0.83, p=0.002). An integrative transomics approach identified multiple candidate genes for heart failure traits, with rs77059055 in TPM1 remaining statistically significant in the UK Biobank (OR 0.83; P=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: